Propranolol hydrochloride extended release - Cranford Pharmaceuticals

Drug Profile

Propranolol hydrochloride extended release - Cranford Pharmaceuticals

Alternative Names: Inderal XL; Sustained release propranolol hydrochloride - Cranford Pharmaceuticals

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Holmdel Pharmaceuticals
  • Developer Cranford Pharmaceuticals
  • Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 06 Jul 2017 Chemical structure information added
  • 24 Feb 2017 ANI Pharmaceuticals acquires Propranolol hydrochloride from Cranford pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top